Type
- Laboratory test report (328)
- ARTG (290)
- Cancellation by sponsor (251)
- Australian Public Assessment Report (AusPAR) (29)
- Prescription medicine registration (27)
- Section 14, TGO91 consent (23)
- Designation or determination (7)
- Prescription medicine decision summary (7)
- Prescription medicine evaluation (4)
Date
- 2023 (2)
- 2022 (20)
- 2021 (119)
- 2020 (214)
- 2019 (156)
- 2018 (93)
- 2017 (78)
- 2016 (27)
- 2015 (14)
- 2014 (25)
- 2013 (9)
- 2012 (5)
- 2011 (1)
- 2010 (2)
- 2009 (17)
- 2008 (6)
- 2007 (16)
- 2006 (16)
- 2005 (17)
- 2004 (5)
- 2003 (8)
- 2002 (8)
- 2001 (6)
- 2000 (14)
- 1999 (7)
- 1998 (4)
- 1997 (2)
- 1996 (17)
- 1995 (5)
- 1994 (10)
- 1993 (8)
- 1992 (1)
- 1991 (34)
Sponsor content
966 result(s) found, displaying 1 to 10
- Australian Public Assessment Report (AusPAR)AusPAR: DupixentAusPAR for DUPIXENT dupilumab for the treatment of asthma.
- ARTGSanofi-Aventis Australia Pty Ltd - Specimen receptacle IVDs (402226)Australian Register of Therapeutic Goods (ARTG) information for Sanofi-Aventis Australia Pty Ltd - Specimen receptacle IVDs.
- Australian Public Assessment Report (AusPAR)AusPAR: NexviazymeAusPAR for NEXVIAZYME (avalglucosidase alfa) for long-term enzyme replacement therapy for the treatment of Pompe disease.
- Prescription medicine decision summaryVerorabVerorab (inactivated rabies virus) is approved to treat rabies.
- ARTGPRALUENT alirocumab (rch) 300 mg/2 mL solution for injection pre-filled pen (377452)Australian Register of Therapeutic Goods (ARTG) information for PRALUENT alirocumab (rch) 300 mg/2 mL solution for injection pre-filled pen.
- ARTGVerorab rabies virus vaccine (inactivated) 3.25 IU powder for injection vial with diluent pre-filled syringe with attached needle (371727)Australian Register of Therapeutic Goods (ARTG) information for Verorab rabies virus vaccine (inactivated) 3.25 IU powder for injection vial with diluent pre-filled syringe with attached needle.
- Australian Public Assessment Report (AusPAR)AusPAR: LibtayoAusPAR for LIBTAYO (cemiplimab) for treatment of adult patients with locally advanced and metastatic basal cell carcinoma.
- Prescription medicine registrationVERORAB (Sanofi-Aventis Australia Pty Ltd)Active ingredients: Rabies virus.
- Oct-2022Prescription medicine evaluationXENPOZYME Sanofi-Aventis Australia Pty LtdActive ingredient: olipudase alfa.
- ARTGLantus Vial (396268)Australian Register of Therapeutic Goods (ARTG) information for Lantus Vial.